FogPharma, based in Cambridge, Mass., was founded in 2016 by several scientists including Gregory Verdine, the company’s chairman and CEO, Weiging Zhou, David Lane, and Gerard Hilinski. The company, which was valued at $406 million in November 2022, is developing a new class of drugs designed to treat cancerous tumors that have remained elusive to other approaches.

In November 2022, FogPharma closed a $178 million Series D round led by a group of investors including Arch Venture Partners and Invus.

These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO.

Register for Details

For more details on financing and valuation for FogPharma, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn more about FogPharma

Forge green plus iconForge green minus icon

What is FogPharma's IPO price?

The IPO price for FogPharma will be known only if it becomes public. However, you may access the "Price At Last Round" and the "Implied EV" for publicly traded comparable companies with Forge Data.
Forge green plus iconForge green minus icon

Can you invest in FogPharma?

FogPharma is a privately held company and is not publicly traded on NYSE or NASDAQ in the U.S. To buy pre-IPO shares of a private company, you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.

Forge green plus iconForge green minus icon

Can you sell FogPharma shares pre-IPO?

If you own FogPharma pre-IPO shares and are considering selling, you can find what your shares could be worth on Forge’s secondary marketplace.

Our Private Market Specialists are available to answer any questions you might have and can help connect you with a buyer from our network of 125,000 accredited investors and institutions. You can also learn more about how to sell your private shares before getting started.

Forge green plus iconForge green minus icon

Is FogPharma a publicly traded company?

FogPharma is a private company and not publicly traded.

If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.

Forge green plus iconForge green minus icon

What is FogPharma's funding to date?

FogPharma has raised $506.63MM to date.
Forge green plus iconForge green minus icon

When was FogPharma founded?

FogPharma was founded in 2016.

Who are FogPharma's major investors?

Casdin Capital
General Catalyst
Ra Capital Management
Arch Venture Partners
Fidelity Management & Research
T. Rowe Price
Horizons Ventures
Foresite Capital
Farallon Capital Management
Rock Springs Capital
Deerfield Management
Cormorant Asset Management
The Invus Group
Samsara Biocapital
Catalio Capital Management
Sixty Degree Capital
SymBiosis Capital Management
HBM Healthcare Investments
WuXi AppTec
6 Dimensions Capital
Milky Way Investments Group
Blue Pool Capital
Leerink Partners
Pivotal Life Sciences
Boyu Capital

FogPharma funding rounds and last known valuation

Date Funding Round Funding Raised Price per Share Last Known Valuation

Series E

$145MM raised $XXX.XX $XXX.XX

Series D

$178MM raised $XXX.XX $XXX.XX

Series C

$107MM raised $XXX.XX $XXX.XX

Series B

$65.51MM raised $XXX.XX $XXX.XX

Series A

$11.11MM raised $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data
Updated on: Jun 24, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.